186 related articles for article (PubMed ID: 33934557)
1. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S; Sharma KP; Fan L; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
[TBL] [Abstract][Full Text] [Related]
2. Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.
Shahangian S; Fan L; Sharma KP; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1352. PubMed ID: 33932150
[TBL] [Abstract][Full Text] [Related]
3. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen testing among the elderly in community-based family medicine practices.
Hudson SV; Ohman-Strickland P; Ferrante JM; Lu-Yao G; Orzano AJ; Crabtree BF
J Am Board Fam Med; 2009; 22(3):257-65. PubMed ID: 19429731
[TBL] [Abstract][Full Text] [Related]
6. US guideline may have led to drop in PSA testing among primary care physicians, studies find.
McCarthy M
BMJ; 2015 May; 350():h2906. PubMed ID: 26021822
[No Abstract] [Full Text] [Related]
7. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials.
Goodwin JS; Tan A; Jaramillo E; Kuo YF
J Natl Cancer Inst; 2013 May; 105(10):743-5. PubMed ID: 23459245
[TBL] [Abstract][Full Text] [Related]
8. Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations.
Zavaski ME; Meyer CP; Sammon JD; Hanske J; Gupta S; Sun M; Trinh QD
JAMA Intern Med; 2016 Apr; 176(4):546-7. PubMed ID: 26857148
[No Abstract] [Full Text] [Related]
9. Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure.
Carey M; Bryant J; Yoong SL; Russell G; Barker D; Sanson-Fisher R
BMC Fam Pract; 2013 Dec; 14():186. PubMed ID: 24321004
[TBL] [Abstract][Full Text] [Related]
10. PSA testing for men at average risk of prostate cancer.
Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
[TBL] [Abstract][Full Text] [Related]
11. Relevance of total PSA and free PSA prescriptions.
Lamy PJ; Brouillet JP; Bermont L; Fouillet G; Loric S
Ann Biol Clin (Paris); 2018 Dec; 76(6):659-663. PubMed ID: 30543191
[TBL] [Abstract][Full Text] [Related]
12. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.
Frendl DM; Epstein MM; Fouayzi H; Krajenta R; Rybicki BA; Sokoloff MH
Cancer Causes Control; 2020 Sep; 31(9):861-867. PubMed ID: 32556947
[TBL] [Abstract][Full Text] [Related]
14. Use of Prostate-Specific Antigen Testing Is in the Eye of the Beholder.
Aaronson DS; Redberg RF
JAMA Intern Med; 2016 Apr; 176(4):547-8. PubMed ID: 26856746
[No Abstract] [Full Text] [Related]
15. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.
Kim SP; Karnes RJ; Nguyen PL; Ziegenfuss JY; Thompson RH; Han LC; Shah ND; Smaldone MC; Gross CP; Frank I; Weight CJ; Beebe TJ; Tilburt JC
BJU Int; 2014 May; 113(5b):E106-11. PubMed ID: 24053213
[TBL] [Abstract][Full Text] [Related]
16. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen screening: An update of physician beliefs and practices.
Hall IJ; Rim SH; Massetti GM; Thomas CC; Li J; Richardson LC
Prev Med; 2017 Oct; 103():66-69. PubMed ID: 28793236
[TBL] [Abstract][Full Text] [Related]
18. Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis.
Garg V; Raisch DW; Selig JP; Thompson TA
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):193-203. PubMed ID: 23399779
[TBL] [Abstract][Full Text] [Related]
19. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.
Bynum J; Song Y; Fisher E
J Am Geriatr Soc; 2010 Apr; 58(4):674-80. PubMed ID: 20345867
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
